# An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer

> **NCT00051779** · PHASE1 · COMPLETED · sponsor: **Chugai Pharma USA**

## Conditions studied

- Breast Neoplasms
- Breast Cancer
- Metastasis

## Interventions

- **DRUG:** CAL

## Key facts

- **NCT ID:** NCT00051779
- **Lead sponsor:** Chugai Pharma USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00051779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00051779, "An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT00051779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*